AKTX

Akari Therapeutics, Plc

Price Chart

Latest Quote

$0.24

Current Price

Previous Close	$0.23
Open	$0.24
Day High	$0.25
Day Low	$0.24
Volume	174,912

Fetched: 2026-02-03T09:09:05

Stock Information

Shares Outstanding	35.74M
Total Debt	$2.22M
Cash Equivalents	$2.48M
Net Income	$-15.77M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$8.47M
P/E Ratio	inf
Exchange	NCM

🌐 Visit Website

📊 Custom Metrics & Score

Score: 8/42

Debt to Equity	0.15
Debt to Earnings	-0.16
Current Ratio	0.15
Quick Ratio	0.13

Return on Equity	-89.03%
Avg FCF Growth	-8.35%
FCF Yield	-148.19%

Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.

Recent Price History

Date	Close	Volume
2026-02-02	$0.24	175,000
2026-01-30	$0.23	104,400
2026-01-29	$0.23	604,300
2026-01-28	$0.25	429,300
2026-01-27	$0.28	511,900
2026-01-26	$0.27	1,142,700
2026-01-23	$0.27	406,200
2026-01-22	$0.27	500,900
2026-01-21	$0.26	248,000
2026-01-20	$0.26	92,200
2026-01-16	$0.28	313,800
2026-01-15	$0.27	400,200
2026-01-14	$0.27	238,600
2026-01-13	$0.28	217,400
2026-01-12	$0.28	366,100
2026-01-09	$0.28	453,900
2026-01-08	$0.28	511,400
2026-01-07	$0.29	346,000
2026-01-06	$0.29	432,100
2026-01-05	$0.29	408,400

About Akari Therapeutics, Plc

Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.

📰 Latest News

European Equities Traded in the US as American Depositary Receipts Edge Lower in Friday Trading; Up for Week

MT Newswires • 2026-01-30T16:14:34Z

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Up 1.4% for Week

MT Newswires • 2026-01-23T16:06:21Z

MarketBeat Week in Review – 01/12 - 01/16

MarketBeat • 2026-01-17T12:00:00Z

European Equities Traded in the US as American Depositary Receipts Rise Slightly in Tuesday Trading

MT Newswires • 2026-01-13T16:10:17Z

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading

MT Newswires • 2026-01-09T16:14:25Z

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

MT Newswires • 2025-12-24T16:14:55Z

Insiders Who Purchased US$1.81m Of Akari Therapeutics Stock May Not Have Expected 36% Tumble

Simply Wall St. • 2025-12-23T10:43:21Z

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

MT Newswires • 2025-12-22T16:12:29Z

European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading

MT Newswires • 2025-12-18T16:05:50Z

European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week

MT Newswires • 2025-12-12T16:17:46Z

Income Statement (Annual)

Revenue

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0

Expenses

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Interest Expense	$244,000	$0	-	-
Total Expenses	$16,647,000	$16,806,000	$23,088,000	$17,214,136
Other Income Expense	$-2,908,000	$6,716,000	$5,294,000	$-220,701
Other Non Operating Income Expenses	$-3,000	$-19,000	$-142,000	$-27,482
Net Non Operating Interest Income Expense	$-236,000	$82,000	$46,000	$10,600
Interest Expense Non Operating	$244,000	$0	-	-
Operating Expense	$16,647,000	$16,806,000	$23,088,000	$17,214,136
General And Administrative Expense	$9,664,000	$11,356,000	$13,527,000	$8,080,681

Income & Earnings

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Net Income From Continuing Operation Net Minority Interest	$-19,791,000	$-10,008,000	$-17,748,000	$-17,424,237
Net Interest Income	$-236,000	$82,000	$46,000	$10,600
Interest Income	$8,000	$82,000	$46,000	$10,600
Normalized Income	$-16,886,000	$-16,743,000	$-23,184,000	$-17,231,018
Net Income From Continuing And Discontinued Operation	$-19,791,000	$-10,008,000	$-17,748,000	$-17,424,237
Total Operating Income As Reported	$-21,643,000	$-16,806,000	$-23,088,000	$-17,214,136
Net Income Common Stockholders	$-19,791,000	$-10,008,000	$-17,748,000	$-17,424,237
Net Income	$-19,791,000	$-10,008,000	$-17,748,000	$-17,424,237
Net Income Including Noncontrolling Interests	$-19,791,000	$-10,008,000	$-17,748,000	$-17,424,237
Net Income Continuous Operations	$-19,791,000	$-10,008,000	$-17,748,000	$-17,424,237
Pretax Income	$-19,791,000	$-10,008,000	$-17,748,000	$-17,424,237
Special Income Charges	$-4,996,000	$0	-	-
Interest Income Non Operating	$8,000	$82,000	$46,000	$10,600
Operating Income	$-16,647,000	$-16,806,000	$-23,088,000	$-17,214,136

Per Share Metrics

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Diluted EPS	$0.00	$0.00	$-5.40	$-8.12
Basic EPS	$0.00	$0.00	$-5.40	$-8.12

Other

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-16,628,000	$-16,739,000	$-28,520,000	$-17,016,791
Total Unusual Items	$-2,905,000	$6,735,000	$5,436,000	$-193,219
Total Unusual Items Excluding Goodwill	$-2,905,000	$6,735,000	$5,436,000	$-193,219
Reconciled Depreciation	$14,000	$4,000	$4,000	$4,126
EBITDA (Bullshit earnings)	$-19,533,000	$-10,004,000	$-23,084,000	$-17,210,010
EBIT	$-19,547,000	$-10,008,000	$-23,088,000	$-17,214,136
Diluted Average Shares	$11,944,005	$4,894,490	$3,121,731	$2,146,056
Basic Average Shares	$11,944,005	$4,894,490	$3,121,731	$2,146,056
Diluted NI Availto Com Stockholders	$-19,791,000	$-10,008,000	$-17,748,000	$-17,424,237
Restructuring And Mergern Acquisition	$4,996,000	$0	-	-
Gain On Sale Of Security	$2,091,000	$6,735,000	$5,436,000	$-193,219
Research And Development	$6,983,000	$5,450,000	$9,561,000	$9,133,455
Selling General And Administration	$9,664,000	$11,356,000	$13,527,000	$8,080,681
Other Gand A	$9,664,000	$11,356,000	$13,527,000	$8,080,681

Fetched: 2026-02-02

Balance Sheet (Annual)

Assets

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Net Tangible Assets	$-25,381,000	$-243,000	$1,774,000	$5,531,653
Total Assets	$50,562,000	$4,355,000	$13,832,000	$11,648,028
Total Non Current Assets	$47,610,000	$14,000	$17,000	$22,929
Goodwill And Other Intangible Assets	$47,610,000	$14,000	$17,000	$22,929
Other Intangible Assets	$39,180,000	$14,000	$17,000	$22,929
Current Assets	$2,952,000	$4,341,000	$13,815,000	$11,625,099
Other Current Assets	$201,000	$197,000	$100,000	$90,301
Restricted Cash	$60,000	$0	-	-
Prepaid Assets	$92,000	$299,000	$465,000	$2,173,528
Cash Cash Equivalents And Short Term Investments	$2,599,000	$3,845,000	$13,250,000	$9,361,270
Cash And Cash Equivalents	$2,599,000	$3,845,000	$13,250,000	$9,361,270
Cash Financial	$2,599,000	$3,845,000	$13,250,000	$9,361,270

Debt

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Net Debt	$661,000	-	-	-
Total Debt	$3,260,000	-	-	-
Current Debt And Capital Lease Obligation	$3,260,000	-	-	-
Current Debt	$3,260,000	-	-	-
Other Current Borrowings	$950,000	-	-	-

Liabilities

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Liabilities Net Minority Interest	$28,333,000	$4,584,000	$12,041,000	$6,093,446
Total Non Current Liabilities Net Minority Interest	$8,423,000	$0	$0	$0
Other Non Current Liabilities	$383,000	-	-	-
Non Current Deferred Liabilities	$8,040,000	$0	-	-
Non Current Deferred Taxes Liabilities	$8,040,000	$0	-	-
Current Liabilities	$19,910,000	$4,584,000	$12,041,000	$6,093,446
Other Current Liabilities	$1,106,000	$1,347,000	$7,946,000	$1,120,000
Current Notes Payable	$2,310,000	$0	-	-
Payables And Accrued Expenses	$15,071,000	$3,050,000	$2,669,000	$4,973,446
Payables	$12,407,000	$1,671,000	$947,000	$1,788,563
Accounts Payable	$12,407,000	$1,671,000	$947,000	$1,788,563

Equity

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Common Stock Equity	$22,229,000	$-229,000	$1,791,000	$5,554,582
Total Equity Gross Minority Interest	$22,229,000	$-229,000	$1,791,000	$5,554,582
Stockholders Equity	$22,229,000	$-229,000	$1,791,000	$5,554,582
Gains Losses Not Affecting Retained Earnings	$-738,000	$-1,040,000	$-771,000	$-540,967
Other Equity Adjustments	$-738,000	$-1,040,000	$-771,000	$-540,967
Retained Earnings	$-247,252,000	$-227,461,000	$-217,453,000	$-199,705,048

Other

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Ordinary Shares Number	$53,186,919,523	$13,234,315,298	$7,444,917,123	$4,759,731,923
Share Issued	$53,186,919,523	$13,234,315,298	$7,444,917,123	$4,759,731,923
Tangible Book Value	$-25,381,000	$-243,000	$1,774,000	$5,531,653
Invested Capital	$25,489,000	$-229,000	$1,791,000	$5,554,582
Working Capital	$-16,958,000	$-243,000	$1,774,000	$5,531,653
Total Capitalization	$22,229,000	$-229,000	$1,791,000	$5,554,582
Additional Paid In Capital	$264,900,000	$226,948,000	$219,270,000	$205,324,624
Capital Stock	$5,319,000	$1,324,000	$745,000	$475,973
Common Stock	$5,319,000	$1,324,000	$745,000	$475,973
Pensionand Other Post Retirement Benefit Plans Current	$473,000	$187,000	$1,426,000	-
Current Accrued Expenses	$2,664,000	$1,379,000	$1,722,000	$3,184,883
Goodwill	$8,430,000	-	-	-
Net PPE	-	-	-	$0
Accumulated Depreciation	-	-	-	$-164,938
Gross PPE	-	-	-	$164,938
Machinery Furniture Equipment	-	-	-	$164,938

Fetched: 2026-02-02

Cash Flow Statement (Annual)

Free Cash Flow

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Free Cash Flow	$-12,552,000	$-16,432,000	$-21,504,000	$-18,846,528

Operating Activities

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Operating Cash Flow	$-12,552,000	$-16,432,000	$-21,504,000	$-18,846,528
Cash Flow From Continuing Operating Activities	$-12,552,000	$-16,432,000	$-21,504,000	$-18,846,528
Operating Gains Losses	$-1,830,000	$-6,854,000	$-5,317,000	$242,503

Investing Activities

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Investing Cash Flow	$382,000	$0	-	-
Cash Flow From Continuing Investing Activities	$382,000	$0	-	-

Financing Activities

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Issuance Of Capital Stock	$11,815,000	$7,016,000	$25,194,000	$14,292,753
Financing Cash Flow	$10,988,000	$7,020,000	$25,288,000	$14,292,753
Cash Flow From Continuing Financing Activities	$10,988,000	$7,020,000	$25,288,000	$14,292,753
Net Common Stock Issuance	$11,815,000	$7,016,000	$25,194,000	$14,292,753
Common Stock Issuance	$11,815,000	$7,016,000	$25,194,000	$14,292,753

Other

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Repayment Of Debt	$-1,855,000	$0	-	-
Issuance Of Debt	$1,000,000	$0	-	-
Interest Paid Supplemental Data	$143,000	$0	-	-
End Cash Position	$2,659,000	$3,845,000	$13,250,000	$9,361,270
Beginning Cash Position	$3,845,000	$13,250,000	$9,361,000	$14,055,777
Effect Of Exchange Rate Changes	$-4,000	$7,000	$105,000	$-140,732
Changes In Cash	$-1,182,000	$-9,412,000	$3,784,000	$-4,553,775
Proceeds From Stock Option Exercised	$28,000	$4,000	$94,000	$0
Net Issuance Payments Of Debt	$-855,000	$0	-	-
Net Short Term Debt Issuance	$-855,000	$0	-	-
Short Term Debt Payments	$-1,855,000	$0	-	-
Short Term Debt Issuance	$1,000,000	$0	-	-
Net Business Purchase And Sale	$382,000	$0	-	-
Sale Of Business	$382,000	$0	-	-
Change In Working Capital	$6,539,000	$-866,000	$822,000	$-1,983,570
Change In Payables And Accrued Expense	$5,223,000	$-936,000	$-877,000	$-241,309
Change In Prepaid Assets	$1,316,000	$70,000	$1,699,000	$-1,742,261
Other Non Cash Items	$271,000	$142,000	-	-
Stock Based Compensation	$2,245,000	$1,150,000	$735,000	$314,650
Depreciation Amortization Depletion	$14,000	$4,000	$4,000	$4,126
Depreciation And Amortization	$14,000	$4,000	$4,000	$4,126
Gain Loss On Investment Securities	$-2,085,000	$-6,599,000	$-4,983,000	-
Net Foreign Currency Exchange Gain Loss	$255,000	$-255,000	$-334,000	$242,503
Net Income From Continuing Operations	$-19,791,000	$-10,008,000	$-17,748,000	$-17,424,237

Fetched: 2026-02-02